Taiwan
· Delayed Price · Currency is TWD BRIM Biotechnology Statistics
Total Valuation
BRIM Biotechnology has a market cap or net worth of TWD 5.00 billion. The enterprise value is 3.54 billion.
| Market Cap | 5.00B |
| Enterprise Value | 3.54B |
Important Dates
The last earnings date was Wednesday, November 13, 2024.
| Earnings Date | Nov 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
BRIM Biotechnology has 115.75 million shares outstanding. The number of shares has increased by 23.87% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 115.75M |
| Shares Change (YoY) | +23.87% |
| Shares Change (QoQ) | +0.16% |
| Owned by Insiders (%) | 4.33% |
| Owned by Institutions (%) | 1.47% |
| Float | 97.04M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 3.23 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -7.58 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -8.28 |
Financial Position
The company has a current ratio of 58.90, with a Debt / Equity ratio of 0.00.
| Current Ratio | 58.90 |
| Quick Ratio | 58.37 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.00 |
| Interest Coverage | -6,271.00 |
Financial Efficiency
Return on equity (ROE) is -28.40% and return on invested capital (ROIC) is -18.58%.
| Return on Equity (ROE) | -28.40% |
| Return on Assets (ROA) | -18.23% |
| Return on Capital (ROIC) | -18.58% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -43.28% in the last 52 weeks. The beta is 1.17, so BRIM Biotechnology's price volatility has been higher than the market average.
| Beta (5Y) | 1.17 |
| 52-Week Price Change | -43.28% |
| 50-Day Moving Average | 44.62 |
| 200-Day Moving Average | 38.86 |
| Relative Strength Index (RSI) | 50.16 |
| Average Volume (20 Days) | 374,137 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BRIM Biotechnology had revenue of TWD 111,000 and -466.63 million in losses. Loss per share was -4.10.
| Revenue | 111,000 |
| Gross Profit | 51,000 |
| Operating Income | -489.14M |
| Pretax Income | -466.63M |
| Net Income | -466.63M |
| EBITDA | -483.95M |
| EBIT | -489.14M |
| Loss Per Share | -4.10 |
Balance Sheet
The company has 1.46 billion in cash and 544,000 in debt, giving a net cash position of 1.46 billion or 12.65 per share.
| Cash & Cash Equivalents | 1.46B |
| Total Debt | 544,000 |
| Net Cash | 1.46B |
| Net Cash Per Share | 12.65 |
| Equity (Book Value) | 1.55B |
| Book Value Per Share | 13.37 |
| Working Capital | 1.46B |
Cash Flow
In the last 12 months, operating cash flow was -424.56 million and capital expenditures -2.44 million, giving a free cash flow of -427.00 million.
| Operating Cash Flow | -424.56M |
| Capital Expenditures | -2.44M |
| Free Cash Flow | -427.00M |
| FCF Per Share | -3.69 |
Margins
| Gross Margin | 45.95% |
| Operating Margin | -440,664.86% |
| Pretax Margin | -420,384.68% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -384,684.23% |
Dividends & Yields
BRIM Biotechnology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -23.87% |
| Shareholder Yield | -23.87% |
| Earnings Yield | -9.49% |
| FCF Yield | -8.54% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |